Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

The effects of shortened dexamethasone administration on remission rate and potential complications during remission induction treatment for pediatric acute lymphoblastic leukemia

급성림프구성백혈병 환아의 관해유도 치료 중 덱사메타손 투여기간의 단축이 관해유도율 및 합병증 발생에 미치는 영향

  • Lee, Jae Wook (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Lee, Kwang Hee (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Kwon, Young Joo (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Lee, Dae Hyoung (Department of Pediatrics, College of Medicine, Hallym University) ;
  • Chung, Nak Gyun (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Jeong, Dae Chul (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Cho, Bin (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Kim, Hack Ki (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
  • 이재욱 (가톨릭대학교 의과대학 소아과학교실) ;
  • 이광희 (가톨릭대학교 의과대학 소아과학교실) ;
  • 권영주 (가톨릭대학교 의과대학 소아과학교실) ;
  • 이대형 (한림대학교 의과대학 소아과학교실) ;
  • 정낙균 (가톨릭대학교 의과대학 소아과학교실) ;
  • 정대철 (가톨릭대학교 의과대학 소아과학교실) ;
  • 조빈 (가톨릭대학교 의과대학 소아과학교실) ;
  • 김학기 (가톨릭대학교 의과대학 소아과학교실)
  • Received : 2007.09.10
  • Accepted : 2007.10.10
  • Published : 2007.12.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : Due to its high potency against leukemic blasts, our institution has opted for the use of dexamethasone during acute lymphoblastic leukemia (ALL) remission induction, but in our most recent treatment protocol, CMCPL-2005, we shortened the length of steroid treatment from 4 to 3 weeks. We compared both the rates of remission induction and significant complications observed during induction with CMCPL-2005, with those noted for our previous protocol, CMCPL-2001. Methods : We retrospectively reviewed the records of patients diagnosed with ALL from January, 2001 to December, 2006 at the Department of Pediatrics, St. Mary's Hospital, the Catholic University of Korea. Data concerning age, sex, WBC count at diagnosis, immunophenotype, cytogenetic traits, and risk group were collected for each patient. Results of remission induction treatment were compared between the two patient groups. Infection and other major complications resulting from treatment were investigated according to NCI toxicity criteria. Results : A total of 141 and 88 patients received remission induction under CMCPL-2001 and CMCPL-2005 respectively. In the CMCPL-2001 group, 136 (96%) achieved complete remission while 82 (93%) achieved CR in the CMCPL-2005 group. Patients in the CMCPL-2005 group were more likely to undergo remission induction without experiencing major complications. However, with regards to steroid related toxicities such as infection, no significant differences were noted. Conclusion : We shortened the length of steroid administration from four to three weeks, yet found the remission induction rate to be comparable to that of our previous regimen. However, rates of steroid related toxicities such as infectious complications remain unchanged despite shortened exposure to dexamethasone.

목 적 : 소아 ALL 관해유도 시 스테로이드는 중추적인 역할을 하는 약제로 덱사메타손은 프레드니솔론에 비해 항백혈병 효과가 우수하지만 감염, 혈당 불내성, 골 괴사 등의 합병증의 가능성도 높다. 본원에서는 백혈병 세포에 대한 높은 항암효과를 고려하여 관해유도 시 덱사메타손을 사용했지만 이 약제에 의한 합병증 감소를 위해 2005년부터 시행한 치료지침(CMCPL-2005)에는 덱사메타손의 투여기간을 총 4주에서 3주로 일주일 단축해서 투여하였다. 이에 저자들은 수정한 치료지침의 관해유도율 및 주요 합병증 발생률을 기존지침(CMCPL-2001)의 성적과 비교 분석하기로 하였다. 방 법 : 가톨릭대학교 성모병원 소아과에서 2001년 1월부터 2006년 12월까지 ALL로 진단 받은 환아들의 기록을 후향적으로 조사하였다. 2001년 1월부터 2004년 12월까지 기간 동안 ALL을 진단받은 환아들은 CMCPL-2001지침 하에 관해유도를 받았고 2005년 이후에 진단받은 환아들은 CMCPL-2005지침 하에 관해유도를 받았다. 대상 환아에 대한 기초자료로 나이, 성별, 진단 시 백혈구 수, 면역표현형, 세포유전학적 특징, 그리고 위험군 분류에 대해 조사하였다. 각 CMCPL-2001 및 CMCPL-2005군의 전처치 기간 동안의 스테로이드 투여에 대한 반응을 확인하고 관해유도 결과를 분석하였다. 관해유도를 위해 입원한 기간 동안 발생한 감염, 간독성, 신경계, 위장관계, 내분비계 합병증 등은 NCI 독성 기준분류를 토대로 조사하였다. 결 과 : 총 141명이 CMCPL-2001지침으로, 88명이 CMCPL- 2005지침으로 관해유도를 받았다. 고위험군에 해당하는 10세 이상 환아, 예후 불량인자에 포함되는 염색체전위가 CMCPL-2005군에 유의하게 많았다. CMCPL-2001군에서는 총 132례(94%), CMCPL-2005군에서는 81례(92%)가 전처치 스테로이드에 양호한 반응을 보여 통계적인 차이는 없었고 관해유도 치료 후 시행한 골수검사에서도 CMCPL-2001군에서는 136례(96%), CMCPL- 2005군에서는 82례(93%)가 완전관해를 보여 동등한 치료성적을 보였다. CMCPL-2005군이 신경계, 위장관계, 심혈관계 등의 스테로이드와 연관된 합병증 없이 관해유도를 받을 확률이 CMCPL- 2001군보다 높았지만 감염성 합병증과 같은 중증합병증에 대해서는 두 군간에 차이가 없었다. 결 론 : 소아 ALL의 관해유도 치료지침에서 덱사메타손의 투여를 일주일 단축해도 기존의 4주간 스테로이드 투여방법과 동등한 관해 유도율을 확인하였으나 감염성 합병증 등 스테로이드 투여와 연관된 합병증의 감소는 없었다.

Keywords

References

  1. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998;339:605-15 https://doi.org/10.1056/NEJM199808273390907
  2. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-78 https://doi.org/10.1056/NEJMra052603
  3. Ito C, Evans WE, McNinch L, Coustan-Smith E, Mahmoud H, Pui CH, et al. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol 1996;14:2370-6 https://doi.org/10.1200/JCO.1996.14.8.2370
  4. Jones B, Freeman AI, Shuster JJ, Jacquillat C, Weil M, Pochedly C, et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 1991;19:269-75 https://doi.org/10.1002/mpo.2950190411
  5. Belgaumi AF, Al-Bakrah M, Al-Mahr M, Al-Jefri A, Al- Musa A, Saleh M, et al. Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin. Cancer 2003;97:2898-903 https://doi.org/10.1002/cncr.11390
  6. Hurwitz CA, Silverman LB, Schorin MA, Clavell LA, Dalton VK, Glick KM, et al. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 2000;88:1964-9 https://doi.org/10.1002/(SICI)1097-0142(20000415)88:8<1964::AID-CNCR27>3.0.CO;2-1
  7. Mantadakis E, Danilatou V, Stiakaki E, Kalmanti M. Infectious toxicity of dexamethasone during ALL remission-induction chemotherapy: report of two cases and literature review. Pediatr Hematol Oncol 2004;21:27-35 https://doi.org/10.1080/08880010490263533
  8. Igarashi S, Manabe A, Ohara A, Kumagai M, Saito T, Okimoto Y, et al. No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediaterisk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 Protocol. J Clin Oncol 2005;23:6489-98 https://doi.org/10.1200/JCO.2005.01.982
  9. Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003;101: 3809-17 https://doi.org/10.1182/blood-2002-08-2454
  10. Yetgin S, Tuncer MA, Cetin M, Gumruk F, Yenicesu I, Tunc B, et al. Benefit of high-dose methlyprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up. Leukemia 2003;17:328-33 https://doi.org/10.1038/sj.leu.2402673
  11. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001;97:1211-8 https://doi.org/10.1182/blood.V97.5.1211
  12. Schwartz CL, Thompson EB, Gelber RD, Young ML, Chilton D, Cohen HJ, et al. Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol 2001;19:1040-6 https://doi.org/10.1200/JCO.2001.19.4.1040
  13. Pui C-H. Childhood leukemias. N Engl J Med 1995;332: 1618-30 https://doi.org/10.1056/NEJM199506153322407
  14. Gaynon PS, Desai AA, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer 1997;80:1717-26 https://doi.org/10.1002/(SICI)1097-0142(19971101)80:9<1717::AID-CNCR4>3.0.CO;2-B
  15. Hann I, Vora A, Harrison G, Harrison C, Eden O, Hill F, et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol 2001;113:103-14 https://doi.org/10.1046/j.1365-2141.2001.02668.x
  16. Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84:3122-33
  17. Gaynon PS, Trigg ME, Heerema NA, Sensel MG, Sather HN, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000;14:2223-33
  18. Mattano LA Jr, Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol 2000;18:3262-72 https://doi.org/10.1200/JCO.2000.18.18.3262
  19. Waber DP, Carpentieri SC, Klar N, Silverman LB, Schwenn M, Hurwitz CA, et al. Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. J Pediatr Hematol Oncol 2000;22:206-13 https://doi.org/10.1097/00043426-200005000-00004
  20. Estlin EJ, Ronghe M, Burke GA, Yule SM. The clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase, anthracyclines and cyclophosphamide in relation to childhood acute lymphoblastic leukemia. Br J Haematol 2000;110:780-90 https://doi.org/10.1046/j.1365-2141.2000.t01-1-02153.x
  21. Chung NG, Lee SJ, Kim SY, Jang PS, Cho B, Jeong DC, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. Korean J Pediatr Hematol-Oncol 2003;10:189-97
  22. Biondi A, Cimino G, Pieters R, Pui CH. Biological and therapeutic aspects of infant leukemia. Blood 2000;96:24-33

Cited by

  1. Chromosome abnormalities in T-cell acute lymphoblastic leukemia in Korea vol.99, pp.3, 2007, https://doi.org/10.1007/s12185-014-1513-2